Geneva Capital Management Portfolio holdings
Top Buys
| 1 |
Mesa Laboratories
MLAB
|
+$13.6M |
| 2 |
Blackbaud
BLKB
|
+$9.6M |
| 3 |
SPS Commerce
SPSC
|
+$8.65M |
| 4 |
iShares Russell 2000 Growth ETF
IWO
|
+$8.18M |
| 5 |
Construction Partners
ROAD
|
+$7.25M |
Top Sells
| 1 |
Kinsale Capital Group
KNSL
|
+$35.9M |
| 2 |
LHCG
LHC Group LLC
LHCG
|
+$35.3M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
+$21.9M |
| 4 |
O'Reilly Automotive
ORLY
|
+$7.73M |
| 5 |
PETQ
PetIQ, Inc. Class A Common Stock
PETQ
|
+$5.95M |
Sector Composition
| 1 | Technology | 35.48% |
| 2 | Industrials | 26.91% |
| 3 | Healthcare | 15.32% |
| 4 | Consumer Discretionary | 8.86% |
| 5 | Financials | 6.54% |
Similar funds
Geneva Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Geneva Capital Management held 130 positions worth $4.45B, up 2.8% from $4.33B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Geneva Capital Management withdrew a net $134M in Q4 2022, closing 6 positions and reducing 87 holdings. Its most notable exit was LHC Group LLC, an estimated $35.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 34% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Geneva Capital Management opened a new position in Vanguard Small-Cap Growth ETF worth $2.91M.
- Geneva Capital Management's largest Q4 2022 buy was Vanguard Small-Cap Growth ETF: 14,518 shares worth $2.91M.
- Geneva Capital Management added most to Mesa Laboratories in Q4 2022, an estimated $13.6M increase.
- Geneva Capital Management's biggest Q4 2022 reduction was Kinsale Capital Group, cutting an estimated $35.9M.
- Geneva Capital Management fully exited LHC Group LLC in Q4 2022, selling an estimated $35.3M.
- Geneva Capital Management's ten largest holdings make up 27% of its $4.45B portfolio in Q4 2022.
- Geneva Capital Management opened 2 new positions and closed 6 in Q4 2022.
- Geneva Capital Management's portfolio value rose 2.8% quarter-over-quarter to $4.45B.
Based on Geneva Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.